A group from McMaster University, Canada, etc. has reported about the results of randomized clinical trial for Hydroxychloroquine, Lopinavir, Ritonavir as drugs for COVID-19.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044
The randomized clinical trial was done in Brazil, and the sample size was as follows; A total of 214 participants were randomized to hydroxychloroquine; 244, lopinavir-ritonavir; and 227, placebo.
As for the virological clearance, the results were (odds ratio [OR], 0.91; 95% CI, 0.82-1.02）for hydroxychloroquine and (OR, 1.04; 95% CI, 0.94-1.16) for lopinavir-ritonavir. Neither hydroxychloroquine nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19–associated hospitalization or other secondary clinical outcomes.
For your information,
Hydroxychloroquine：A drug used for malaria and/or rheumatoid arthritis,
Lopinavir：A drug used for HIV HAAR treatment,
Ritonavir：A drug for HIV and HCV treatment.